News
Distribution and Localization of Specifically Modified Exosomes Can Improve the Treatment of Muscular Dystrophies
A research team from several Milanese universities, in a study published in Nature Nanotechnology, focused on developing a new method for muscular dystrophy therapy. Specifically modified exosomes were enriched with the protein annexin A1 and delivered into dystrophic muscle cells using ferromagnetic nanotubes guided by an external magnetic field. This triggered healing processes in damaged cells and tissues in a mouse model.
Scientists Decipher the Perception of Bitter Taste. How Will This Help in the Development of New Drugs?
Taste receptors are a known phenomenon, but how exactly does taste perception occur? Scientists…
New method for distinguishing tumour tissue could improve glioblastoma resection
A research team from the Czech National Institute for Cancer Research (NÚVR) and Stanford…
Cinitapride in the Treatment of Functional Dyspepsia – An Overview and Meta-Analysis of Current Data
Functional dyspepsia is a relatively common disorder of the gastroduodenal tract characterized by symptoms...
A kiss that 'took my legs away': A rare case of EBV in a 70-year-old woman – a case report
A trio of British authors presents the case of a 70-year-old woman evaluated in the emergency…
AI Can Provide Surgeons with Valuable Data and Real-Time Feedback
Artificial intelligence (AI) tools in healthcare are evolving and improving at an ever-accelerating…
Better get your eyes checked! How is visual sensitivity linked to dementia development?
Our vision reveals a lot about the health of our brain. Eye problems may even be one of the…
How and when does the reaction to gluten begin in coeliac disease? A new Canadian study offers potential answers
As is well known, coeliac disease is a systemic autoimmune disorder characterised by damage to…
Could Artificial Intelligence Help with Emergency Department Triage in the Future?
A new study by researchers from the University of California, San Francisco, is one of the few to…
Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
The phase III study cited below evaluated the efficacy and safety of 12-month prophylaxis with recombinant...